Verona Pharma plc

NasdaqGM:VRNA Stock Report

Market Cap: US$5.6b

Verona Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:VRNA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Dec 24SellUS$4,415,452Mark HahnIndividual110,245US$40.07
06 Dec 24SellUS$4,358,787David ZaccardelliIndividual108,834US$40.07
02 Dec 24SellUS$627,233David ZaccardelliIndividual15,666US$40.05
02 Dec 24SellUS$566,822Mark HahnIndividual14,155US$40.05
26 Nov 24SellUS$12,000Mark HahnIndividual300US$40.00
25 Nov 24SellUS$1,176,360Kathleen RickardIndividual30,000US$39.21
25 Nov 24SellUS$8,000David ZaccardelliIndividual200US$40.00
18 Nov 24BuyUS$33,300David EbsworthIndividual2,500US$13.32
11 Nov 24SellUS$12,000Mark HahnIndividual300US$40.00
11 Nov 24SellUS$12,000David ZaccardelliIndividual300US$40.00
06 Nov 24BuyUS$198,386Christina AckermannIndividual5,235US$37.90
06 Nov 24BuyUS$188,881David EbsworthIndividual4,920US$38.39
04 Nov 24SellUS$568,387Mark HahnIndividual16,209US$35.10
04 Nov 24SellUS$618,658David ZaccardelliIndividual17,629US$35.13
25 Oct 24SellUS$633,896David ZaccardelliIndividual18,102US$35.02
25 Oct 24SellUS$632,761Mark HahnIndividual18,070US$35.02
22 Oct 24SellUS$2,303,773Mark HahnIndividual525,768US$4.38
22 Oct 24SellUS$2,253,237David ZaccardelliIndividual514,152US$4.39
11 Sep 24SellUS$2,254,080Mark HahnIndividual600,000US$3.76
11 Sep 24SellUS$2,254,320David ZaccardelliIndividual600,000US$3.76
13 Aug 24SellUS$1,275,540Mark HahnIndividual49,800US$26.00
12 Aug 24BuyUS$103,320David EbsworthIndividual4,500US$22.96
12 Aug 24SellUS$5,008Mark HahnIndividual200US$25.04
12 Aug 24SellUS$5,008David ZaccardelliIndividual200US$25.04
03 May 24SellUS$71,032Kathleen RickardIndividual4,531US$15.68

Insider Trading Volume

Insider Buying: VRNA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of VRNA?
Owner TypeNumber of SharesOwnership Percentage
General Public1,603,0731.96%
Individual Insiders3,443,6174.21%
VC/PE Firms19,754,80124.1%
Institutions57,029,67869.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.5%
RA Capital Management, L.P.
7,777,942US$528.6m-36.3%6.3%
7.81%
Perceptive Advisors LLC
6,392,106US$434.4m1.21%11.16%
6.82%
New Enterprise Associates, Inc.
5,584,753US$379.5m0%17.53%
4.14%
Frazier Life Sciences Management, LP
3,383,950US$230.0m0%9.02%
3.83%
Eventide Asset Management, LLC
3,132,127US$212.9m29.1%3.4%
3.82%
Maverick Capital, Ltd.
3,128,516US$212.6m-25.8%3.34%
3.7%
Wellington Management Group LLP
3,025,241US$205.6m61%0.03%
2.79%
Vivo Capital, LLC
2,283,975US$155.2m-35.7%14.34%
2.32%
Summit Partners Public Asset Management, LLC
1,902,026US$129.3m0%3.61%
2.31%
Jennison Associates LLC
1,889,542US$128.4m8.54%0.07%
2.24%
T. Rowe Price Group, Inc.
1,833,532US$124.6m37.3%0.01%
2.23%
Federated Hermes, Inc.
1,825,293US$124.0m-15.8%0.27%
2.23%
RTW Investments, LP
1,821,019US$123.8m0%1.63%
2.04%
Janus Henderson Group plc
1,667,165US$113.3m59.9%0.04%
1.82%
Hood River Capital Management LLC
1,485,256US$100.9m3.58%1.37%
1.77%
Morgan Stanley, Investment Banking and Brokerage Investments
1,450,472US$98.6m161%0.01%
1.76%
David Zaccardelli
1,439,128US$97.8m2.75%no data
1.76%
Caligan Partners, LP
1,436,878US$97.7m0%20.15%
1.65%
Citadel Advisors LLC
1,352,713US$91.9m14.8%0.08%
1.62%
Mark Hahn
1,325,231US$90.1m2.99%no data
1.36%
Aisling Capital Management LP
1,115,352US$75.8m0%21.24%
1.32%
Loomis Sayles & Company, L.P.
1,079,555US$73.4m-2.84%0.08%
1.17%
Rice Hall James & Associates, LLC
954,616US$64.9m-3.09%3.21%
1.08%
Duquesne Family Office LLC
887,580US$60.3m29.4%1.5%
1.04%
Deep Track Capital, LP
850,000US$57.8m-73.3%1.89%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 03:32
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verona Pharma plc is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Thomas ShraderBTIG
Edward NashCanaccord Genuity